Journal of cardiology最新文献

{"title":"Blood reflux-sensitive microRNAs in venous endothelium are correlated with the development of human chronic venous disease.","authors":"He-Rong Yu, Hsiao-En Tsai, Shun-Fu Chang, Yi-Tsen Yeh, Yu-Zhen Chen, Shin-Yi Wang, Ming-Hua Tsai, Ding-Yu Lee","doi":"10.1016/j.jjcc.2025.05.008","DOIUrl":"10.1016/j.jjcc.2025.05.008","url":null,"abstract":"<p><strong>Background: </strong>Flow-sensitive microRNAs (miRs) (e.g. miR-10a, miR-126-5p, miR-663, and miR-92a) are vital regulators of hemodynamics (i.e. pro-atherogenic or anti-atherogenic flow) that modulate aortic endothelial cell (EC) function and atherosclerosis development. We aimed to determine the roles of flow-sensitive miRs in venous ECs in response to blood reflux and correlate these miRs with chronic venous disease (CVD) development.</p><p><strong>Methods: </strong>In-vivo human studies (i.e. human varicose veins with different levels of blood reflux vs. human normal veins with normal venous flow) and in-vitro flow experiments were used to examine the role of blood reflux in modulating the signaling of miR-10a, miR-126-5p, miR-663, and miR-92a.</p><p><strong>Results: </strong>We found that the expression of anti-inflammatory miR-10a and vascular repair-associated miR-126-5p was inhibited in the endothelium of varicose veins with blood reflux, and the expression of their direct targets, inflammatory GATA6 and anti-proliferative DLK1, was upregulated. In contrast, inflammatory miR-663 and miR-92a were overexpressed in the endothelium of varicose veins with blood reflux, whereas the expression of their targets, anti-inflammatory KLF4 and KLF2, was downregulated. We further demonstrated that blood reflux-induced oscillatory flow plays a major role in the overexpression of GATA6 and DLK1 and the inhibition of KLF4 and KLF2 expression in venous ECs. In-vitro transfection of a precursor miR (i.e. miR-10a or miR-126-5p) or antagomiR (i.e. miR-663 or miR-92a) to venous ECs abolished such blood reflux-induced pathogenic signaling.</p><p><strong>Conclusions: </strong>Our findings indicate that the expression of anti-inflammatory miR-10a and vascular repair-associated miR-126-5p is inhibited, but inflammatory miR-663 and miR-92a are overexpressed in the endothelium of human varicose veins with blood reflux to modulate venous EC pathogenic signaling related to inflammation or turnover imbalance, which is highly related to human CVD progression. Moreover, blood reflux-modulated miRs have the potential to be developed as diagnostic biomarkers or therapeutic targets for human CVD.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary anatomic, functional, and prognostic correlates of ischemic electrocardiographic changes during stress echocardiography.","authors":"Sergio Kobal, Quirino Ciampi, Rosina Arbucci, Angela Zagatina, Elena Kalinina, Ratnasari Padang, Garvan C Kane, Hector R Villarraga, Adelaide M Arruda-Olson, Jesus Peteiro Vazquez, Alla Boshchenko, Tamara Ryabova, Jelena Celutkiene, Ariel Saad, Francesca Bursi, Ana Djordjevic-Dikic, Matteo Lisi, Elisa Merli, Fiore Manganelli, Clarissa Borguezan-Daros, Hugo Rodriguez-Zanella, Maria Grazia D'Alfonso, Fabio Mori, Nicola Gaibazzi, Jaroslaw D Kasprzak, Ayten Safarova, Tatiana Timofeeva, Hugo Mosto, Karina Wierzbowska-Drabik, Nithima Chaowalit Ratanasit, Marco Fabio Costantino, Paolo Colonna, Tamara Kovačević Preradović, Miodrag Ostojic, Lauro Cortigiani, Albert Varga, Aleksandra Nikolic, Rosangela Cocchia, Attila Palinkas, Fausto Rigo, Giovanni Benfari, Filipa Xavier Valente, Dimitrios Soulis, Yi Wang, Lixue Yin, Jorge Lowenstein, Diego M Lowenstein Haber, Sofia Marconi, Giovanni Tripepi, Bruno Villari, Mauro Pepi, Scipione Carerj, Patricia A Pellikka, Eugenio Picano","doi":"10.1016/j.jjcc.2025.05.010","DOIUrl":"10.1016/j.jjcc.2025.05.010","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical appraisal of \"effect of PCSK9 inhibitor usage on coronary endothelial dysfunction in patients with hypercholesterolemia after coronary stenting: the CuVIC-2 trial\".","authors":"Zainab Nouman","doi":"10.1016/j.jjcc.2025.05.007","DOIUrl":"10.1016/j.jjcc.2025.05.007","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac allograft vasculopathy and splenic switch-off: «Off we go»?","authors":"Giandomenico Bisaccia, Joyce Wong, Chiara Bucciarelli-Ducci","doi":"10.1016/j.jjcc.2025.05.009","DOIUrl":"10.1016/j.jjcc.2025.05.009","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of hospitalized patients with heart failure from the Japanese prospective registry.","authors":"Nobuyuki Enzan, Takeshi Tohyama, Tatsuya Watanabe, Takuya Nagata, Eri Noda, Yoshitomo Tsutsui, Masataka Ikeda, Takafumi Sakamoto, Shouji Matsushima, Yuya Matsue, Takeshi Kitai, Tatsunori Taniguchi, Keisuke Kida, Takahiro Okumura, Takuya Kishi, Tomomi Ide, Hiroyuki Tsutsui","doi":"10.1016/j.jjcc.2025.05.015","DOIUrl":"10.1016/j.jjcc.2025.05.015","url":null,"abstract":"<p><strong>Background: </strong>Recent studies showed that clinical parameters other than cardiac function, such as physical function, cognitive function, mental status, social status, and quality of life, were associated with heart failure (HF) prognosis. These parameters have not been extensively investigated in large Japanese cohorts. Furthermore, novel biomarkers to predict prognosis or treatment responses are required to provide individualized medicine. To address these issues, we developed the Japanese Registry Of Acute Decompensated Heart Failure (JROADHF-NEXT).</p><p><strong>Methods: </strong>JROADHF-NEXT is a prospective, multicenter, nationwide registry of patients hospitalized for acute decompensated HF. A total of 4016 patients were enrolled from 87 centers and blood and urine samples were collected from 3203 of these patients. The study protocol using the JROADHF-NEXT database was approved by all Kyushu University, International University of Health and Welfare and participating hospitals.</p><p><strong>Results: </strong>The mean age was 72.9 ± 14.0 years and 61.4 % were male. Cardiomyopathy was the most common etiology (24.4 %). Volume overload and arrhythmia accounted for 26.3 % and 17.4 % of precipitating causes. The median follow-up period was 2.0 (1.6-2.2) years and 2-year follow-up completion rate was 88.5 % (n = 3554). The incidence rates for cardiovascular death and rehospitalization for HF were 5.2 and 16.7 per 100 person-years, respectively.</p><p><strong>Conclusions: </strong>The JROADHF-NEXT is a large-scale HF registry comprising extensive clinical variables with a biobank. This registry is anticipated to provide valuable insights and serve as a significant source of evidence for future research and clinical practice.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critique on \"Mitral regurgitation in atrial fibrillation: Is a simple repair enough to tackle a complex problem?\"","authors":"Abeer Aijaz, Iffat Ambreen Magsi, Izhaan Zeeshan","doi":"10.1016/j.jjcc.2025.05.011","DOIUrl":"10.1016/j.jjcc.2025.05.011","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive ablation in elderly patients with persistent AF: Insights and considerations.","authors":"Cheng Xue","doi":"10.1016/j.jjcc.2025.05.006","DOIUrl":"10.1016/j.jjcc.2025.05.006","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitors and cardiovascular outcomes in patients with left ventricular assist devices.","authors":"Hoang Nhat Pham, Ramzi Ibrahim, Xuan Ci Mee, Ghee Kheng Lim, Mahmoud Abdelnabi, Beani Forst, Patrick Sarkis, George Bcharah, Juan Farina, Chadi Ayoub, Amitoj Singh, Reza Arsanjani, Anwar Chahal, Kwan Lee","doi":"10.1016/j.jjcc.2025.05.004","DOIUrl":"10.1016/j.jjcc.2025.05.004","url":null,"abstract":"<p><strong>Introduction: </strong>Left ventricular assist devices (LVADs) provide critical support for patients with advanced heart failure (HF), but complications and suboptimal outcomes remain challenges. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in HF, but their role in patients with LVADs is not well established. We aimed to evaluate the association of SGLT2 inhibitors with clinical outcomes and heart transplantation rates in patients with LVADs.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the TriNetX Network (2014-2022) to identify all adults (≥18 years old) with LVADs. Patients were stratified into SGLT2 inhibitor users and non-users during LVAD-supported period. Propensity score matching (1:1, PSM) was performed to balance baseline characteristics between two cohorts. Efficacy outcomes included all-cause mortality/hospitalization, HF exacerbations, acute myocardial infarction, cerebral infarction, cardiac arrest, and heart transplant. Safety outcomes included acute kidney injury (AKI), urinary tract infection (UTI), and urogenital candidiasis. Adjusted odds ratios (aORs) with 95 % confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Among 3736 patients with LVADs, 1106 received SGLT2 inhibitors from 2014 to 2022. After PSM, 656 patients were included in each group. SGLT2 inhibitor use was associated with lower risks of all-cause mortality [0.571 (95 % CI, 0.430-0.759)], all-cause hospitalization [aOR 0.619 (0.478-0.802)], acute HF exacerbations [aOR 0.687 (0.539-0.877)], cerebral infarction [aOR 0.676 (0.501-0.912)], and cardiac arrest [aOR 0.441 (0.269-0.725)]. No significant differences were observed for heart transplantation rates [aOR 1.084 (0.834-1.408)] or acute MI [aOR 0.881 (0.663-1.172)]. Safety outcomes favored SGLT2 inhibitor cohort with lower risks of AKI [aOR 0.767 (0.617-0.954)], with no significant difference for UTI [aOR 0.730 (0.527-1.012)] or urogenital candidiasis [aOR 1.000 (0.413-2.419)].</p><p><strong>Conclusions: </strong>SGLT2 inhibitor use in LVAD-supported patients was associated with improved survival, reduced hospitalizations and heart failure exacerbation alongside favorable safety outcomes. These findings support further investigation into SGLT2 inhibitors as a potential adjunctive therapy in the management of patients with LVADs.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of early initiation of mineralocorticoid receptor antagonist therapy in acute decompensated heart failure: A systematic review and meta-analysis.","authors":"Marcello Marchetta, Andrea Giovanni Parato, Giampiero Vizzari, Gaetano Chiricolo, Gianluca Massaro, Giulio Russo, Stefano Sasso, Gabriele Carciotto, Scipione Carerj, Gianluca Di Bella, Andrea Natale, Giuseppe Massimo Sangiorgi, Antonio Micari","doi":"10.1016/j.jjcc.2025.05.005","DOIUrl":"10.1016/j.jjcc.2025.05.005","url":null,"abstract":"<p><strong>Background: </strong>Acute heart failure (AHF) is a major cause of hospitalization, with high morbidity and mortality. Mineralocorticoid receptor antagonists (MRAs) improve outcomes in chronic heart failure, but their role and optimal timing in AHF remain unclear. Early initiation may enhance hemodynamic stability, yet concerns about hyperkalemia and renal dysfunction limit their use. This meta-analysis evaluates the efficacy and safety of early MRA initiation in AHF.</p><p><strong>Methods: </strong>A systematic search of PubMed, SCOPUS, and Cochrane databases identified studies comparing early in-hospital MRA therapy plus standard care versus standard care alone in AHF patients. Pooled odds ratios (OR) with 95 % confidence intervals (CI) were calculated using a random-effects model. Primary outcomes included cardiovascular and all-cause mortality, heart failure rehospitalizations, and safety outcomes (hyperkalemia, renal deterioration, hypotension, and hypokalemia).</p><p><strong>Results: </strong>Six studies (N = 11,039) were included. Early MRA initiation reduced cardiovascular mortality (OR 0.73, 95 % CI 0.59-0.92; p = 0.007), heart failure rehospitalizations (OR 0.56, 95 % CI 0.40-0.78; p = 0.0008), and renal deterioration (OR 0.78, 95 % CI 0.66-0.92; p = 0.003). No significant effect on all-cause mortality was observed (OR 0.88, 95 % CI 0.62-1.24; p = 0.46). A non-significant trend toward increased hyperkalemia emerged (OR 1.45, 95 % CI 0.57-3.68; p = 0.43).</p><p><strong>Conclusion: </strong>This meta-analysis suggests that early MRA initiation in AHF improves cardiovascular outcomes and reduces rehospitalizations with an acceptable safety profile. Further large-scale randomized controlled studies are needed to confirm its long-term clinical impact.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of gut microbiota in cardiovascular diseases and their potential as novel therapeutic targets.","authors":"Tomoya Yamashita","doi":"10.1016/j.jjcc.2025.05.002","DOIUrl":"10.1016/j.jjcc.2025.05.002","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) including heart failure (HF) is a major health, medical and social issue that needs to be resolved in Japan's super-aged society. Recent clinical and basic studies suggest that the gut microbiota and their metabolites play critical roles in the onset and progression of CVDs. We explored changes in gut microbiota composition and metabolite levels among Japanese patients to investigate their association with CVDs. Changes in specific bacteria were observed, with a decrease in phylum Bacteroidetes and increases in order Lactobacillus or genus Streptococcus in coronary artery disease patients. For HF patients, a reduction in phylum Bacteroidetes and increases in phylum Actinobacteria (e.g. Bifidobacterium) and Proteobacteria (e.g. Escherichia, Shigella, and Klebsiella) were noted. Elevated levels of gut microbiota-associated metabolites, such as trimethylamine N-oxide (TMAO) and indoxyl sulfate, were observed in CVD patients, suggesting potential effects on organ functions. Many studies have linked higher plasma TMAO levels to worse prognoses in CVDs, including HF and renal failure. However, the clinical significance and therapeutic potential of these findings require further investigation. In this manuscript, the author aims to review the current status of research on gut microbiota in CVDs, with a primary focus on the microbes themselves and their related metabolites. Further research is essential to comprehensively understand these intricacies and establish clear cause-and-effect relationships, ultimately paving the way for the development of innovative therapies for CVDs.</p>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}